Search research articles
Contact Us
Filters
Showing results (201-210 of 245) with videos related to
Page
of 25
Sort By:
Investigational New Drugs
|
November 6, 2004
An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin
R Goel, E Chouinard, D J Stewart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 1, 1994
Duration of intravenous antibiotics for patients with neutropenic fever
A T Tomiak, J C Yau, S D Huan, et al.
American Journal of Clinical Oncology
|
December 18, 1998
Phase I-II study of 5-fluorouracil, leucovorin, doxorubicin, methotrexate, and long-term oral etoposide (FLAME) in unresectable or metastatic gastric cancer
G A Bjarnason, C Cripps, R Goel, et al.
Oncology Reports
|
April 4, 1998
Effects of PALA on the pharmacokinetics of 5-fluorouracil
M A Nassim, M R Rouini, M C Cripps, et al.
Cancer Chemotherapy and Pharmacology
|
March 11, 2006
A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group
G Goss, L L Siu, I Gauthier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 13, 2006
Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115
J A Maroun, K Belanger, L Seymour, et al.
The Journal of Allergy and Clinical Immunology
|
August 10, 2020
Lupus-like autoimmunity and increased interferon response in patients with STAT3-deficient hyper-IgE syndrome
Rishi R Goel, Shuichiro Nakabo, Brian L P Dizon, et al.
Breast Cancer Research and Treatment
|
February 24, 2001
Liarozole fumarate (R85246): in the treatment of ER negative, tamoxifen refractory or chemotherapy resistant postmenopausal metastatic breast cancer
P E Goss, K Strasser, R Marques, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2003
Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group
C A Townsley, K Chi, D S Ernst, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 26, 2020
Interferon lambda promotes immune dysregulation and tissue inflammation in TLR7-induced lupus
Rishi R Goel, Xinghao Wang, Liam J O'Neil, et al.
Page
of 25
Search research articles
Search
Showing results (201-210 of 245) with videos related to
Sort By:
Page
of 25
Investigational New Drugs
|
November 6, 2004
An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin
R Goel, E Chouinard, D J Stewart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 1, 1994
Duration of intravenous antibiotics for patients with neutropenic fever
A T Tomiak, J C Yau, S D Huan, et al.
American Journal of Clinical Oncology
|
December 18, 1998
Phase I-II study of 5-fluorouracil, leucovorin, doxorubicin, methotrexate, and long-term oral etoposide (FLAME) in unresectable or metastatic gastric cancer
G A Bjarnason, C Cripps, R Goel, et al.
Oncology Reports
|
April 4, 1998
Effects of PALA on the pharmacokinetics of 5-fluorouracil
M A Nassim, M R Rouini, M C Cripps, et al.
Cancer Chemotherapy and Pharmacology
|
March 11, 2006
A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group
G Goss, L L Siu, I Gauthier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 13, 2006
Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115
J A Maroun, K Belanger, L Seymour, et al.
The Journal of Allergy and Clinical Immunology
|
August 10, 2020
Lupus-like autoimmunity and increased interferon response in patients with STAT3-deficient hyper-IgE syndrome
Rishi R Goel, Shuichiro Nakabo, Brian L P Dizon, et al.
Breast Cancer Research and Treatment
|
February 24, 2001
Liarozole fumarate (R85246): in the treatment of ER negative, tamoxifen refractory or chemotherapy resistant postmenopausal metastatic breast cancer
P E Goss, K Strasser, R Marques, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2003
Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group
C A Townsley, K Chi, D S Ernst, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 26, 2020
Interferon lambda promotes immune dysregulation and tissue inflammation in TLR7-induced lupus
Rishi R Goel, Xinghao Wang, Liam J O'Neil, et al.
Page
of 25